Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fred Aslan
AddedMar 31, 2024
UpdatedMay 31, 2026
Fred Aslan

Fred Aslan

Founder & CEO, Adavium Medical

Crunchbase

Fred Aslan's Career

Adavium Medical
Adavium Medical

Palo Alto, CA, US

Founder & CEO· C-Suite · Management
Artiva Biotherapeutics
Artiva Biotherapeutics

San Diego, CA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fred Aslan's Career

Adavium Medical
Adavium Medical
Series C$41M3752011Palo Alto, CA, US
Founder & CEO· C-Suite · Management

Leadership at Adavium Medical

Claudia GoulartClaudia GoulartBoard Member
Paul McCreadiePaul McCreadieBoard Member

Similar to Adavium Medical

Ativa MedicalAtiva MedicalSaint Paul, MN, USMedical Devicesest. 2008Ativa MedicalSaint Paul, MN, US · est. 2008

Ativa Medical: Rapid diagnostic test results through innovative medical device manufacturing.

Series A · $36.2M46
Advanced Medical Device TechnologiesAdvanced Medical Device TechnologiesNewport Beach, CA, USMedical Devicesest. 2019Advanced Medical Device TechnologiesNewport Beach, CA, US · est. 2019

Advanced Medical Device Technologies: Your trusted provider of innovative medical device designs.

Seed · $250k2
AnnoviantAnnoviantAlpharetta, GA, USMedical Devicesest. 2018AnnoviantAlpharetta, GA, US · est. 2018

Annoviant: Innovating healthcare with advanced medical technology development.

Seed · $1.9M30
Advinow MedicalAdvinow MedicalScottsdale, AZ, USMedical Softwareest. 2016Advinow MedicalScottsdale, AZ, US · est. 2016

AdviNOW Medical revolutionizes healthcare with AI and AR, automating patient encounters for efficient, personalized care.

Seed · $14M33
Artiva Biotherapeutics
Artiva Biotherapeutics
Series B$198M782019San Diego, CA, US
CEO· C-Suite · Management

Leadership at Artiva Biotherapeutics

Brian DanielsBrian DanielsBoard Member
Laura StoppelLaura StoppelBoard Member
Peter FlynnPeter FlynnFounder
Linda KozickLinda KozickBoard Member

Fred Aslan's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailBrian KimBrian KimCo-Founder · KakaoKim Beom-sooKim Beom-sooCo-Founder · Kakao

People Similar to Fred Aslan

Jeffrey N. AnkerJeffrey N. AnkerCo-Founder · Aravis BioTechCharles MagolskeCharles MagolskeCo-Founder · Artin BioscienceAdam FieldsAdam FieldsCEO · ArtaF. Nicholas FrananoF. Nicholas FrananoCEO · Novita TherapeuticsTed AcworthTed AcworthFounder · Insightfil